ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Docetaxel

Also written as “docetaxel”, “Taxotere” and “HB1801”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Prostatic Neoplasms · Stomach Neoplasms · Lung Neoplasms, led by 27 companies.

Drug pageDocetaxel: every studyMany companies study it; this page follows only the 142 they lead. All 1,164 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 18, 2006142 company-led studies, 15 open or runningNext primary completion: Dec 16, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only540 open or runningphase 4since Jan 18, 2006Nov 1, 1999none ahead
Hoffmann-La Rocheits history only220 open or runningphase 4since Aug 5, 2005Feb 12, 2004none ahead
CSPC Pharmaceutical Group1511 open or runningphase 3since Apr 20, 2023Mar 10, 2021Dec 16, 2026phase 3 · NCT06747338
Eli Lillyits history only81 open or runningphase 3since Nov 1, 2004Nov 1, 2004May 2027phase 2 · NCT05999994
Pfizerits history only70 open or runningphase 2since Jan 4, 2002Jan 4, 2002none ahead
GlaxoSmithKlineits history only60 open or runningphase 2since Jul 17, 2003Jul 17, 2003none ahead
Amgenits history only40 open or runningphase 2since Jul 5, 2000Jul 5, 2000none ahead
Merckits history only30 open or runningphase 2since Oct 4, 2007Oct 4, 2007none ahead
Novaceaits history only30 open or runningphase 3since Aug 9, 2002Aug 9, 2002none ahead
Novartisits history only20 open or runningphase 3since Jun 29, 2004Jun 29, 2004none ahead

Also a collaborator on its studies: Jazz Pharmaceuticals Ireland, Parexel, Baili-Bio (Chengdu) Pharmaceutical, Clovis Oncology, Astellas Pharma, Exelixis, Gilead Sciences, iTeos Belgium, Intas Pharmaceuticals, Lambda Therapeutic Research, Medigen Biotechnology, US Biotest, Quintiles, MDS Pharma Services, AstraZeneca and Regeneron Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of CSPC Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 10, 2021First study: phase 1 study in Advanced Solid TumorsFirst studyNCT04811118 · 27 enrolled · China
  2. Aug 19, 2021Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT05027204 · 94 enrolled · China
  3. Mar 24, 2022Phase 2 study in Platinum-resistant Recurrent Ovarian CancerNCT05325229 · 94 enrolled · China
  4. Nov 7, 20222 phase 2 studiesNCT05616494, NCT05705635
  5. Apr 20, 2023Phase 3 study in Breast NeoplasmsNCT05838066 · 880 planned · China
  6. May 8, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05863325 · 80 planned · China
  7. Feb 28, 2024Phase 3 study in Stomach NeoplasmsNCT06296706 · 630 planned · China
  8. Mar 13, 2024Phase 3 study in Squamous Cell Non-small Cell Lung CancerNCT06319313 · 534 planned
  9. Jun 24, 2024Phase 3 study in Advanced Pancreatic CancerNCT06492941 · 142 planned
  10. Dec 13, 2024Phase 3 study in Early or Locally Advanced HER2-positive Breast CancerNCT06747338 · 520 enrolled · China
  11. Jul 15, 2025Phase 2 study in Advanced Breast CancerNCT07083505 · 60 planned
  12. Aug 7, 2025Phase 2 study in HER2-positive Breast CancerNCT07116824 · 80 planned
  13. Feb 12, 2026Phase 3 study in Resectable HER2-positive Breast CancerNCT07441460 · 1,800 planned · China
  14. Aug 28, 2026Phase 3 study in HER2-Negative Advanced Breast CancerNCT07805135 · 430 planned

Ahead

  1. Dec 16, 2026Primary completion: phase 3 study in Early or Locally Advanced HER2-positive Breast CancerNCT06747338
  2. Jun 1, 2028Primary completion: phase 3 study in HER2-Negative Advanced Breast CancerNCT07805135
  3. Aug 7, 2034Primary completion: phase 3 study in Resectable HER2-positive Breast CancerNCT07441460

TargetBeta

“Tubulin inhibitor; Tubulin stabiliser”ChEMBL 37, by rule

Other programs on the same 15 targets

ProgramCompanyFurthest phaseStudies
PaclitaxelruleHoffmann-La Rochephase 4202
cabazitaxelruleSanofiphase 421
VinblastineruleTakedaphase 44
desoxyepothilone Brulebeijing-biostar-pharmaceuticals-co-ltdphase 319
plinabulinrulebeyondspring-pharmaceuticals-incphase 38

Studies

All 15 CSPC Pharmaceutical Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07805135HER2-Negative Advanced Breast Cancer3Not yet recruitingJun 1, 2028430
NCT07441460Resectable HER2-positive Breast Cancer · China3RecruitingAug 7, 20341,800
NCT07116824HER2-positive Breast Cancer2Not yet recruitingJul 15, 202680
NCT07083505Advanced Breast Cancer2Not yet recruitingOct 11, 202660
NCT06747338Early or Locally Advanced HER2-positive Breast Cancer · China3Active, not recruitingDec 16, 2026520
NCT06492941Advanced Pancreatic Cancer3Not yet recruitingApr 14, 2026142
NCT06319313Squamous Cell Non-small Cell Lung Cancer3Not yet recruitingJul 1, 2026534
NCT06296706Stomach Neoplasms · China3RecruitingJun 1, 2026630
NCT05863325Carcinoma, Non-Small-Cell Lung · China2RecruitingMar 202480
NCT05838066Breast Neoplasms · China3RecruitingJul 31, 2025880
NCT05705635Gastric Adenocarcinoma · China2UNKNOWNMay 2023100
NCT05616494Pancreatic Neoplasms · China2RecruitingDec 31, 202453
NCT05325229Platinum-resistant Recurrent Ovarian Cancer · China2UNKNOWNDec 202494
NCT05027204Squamous Cell Carcinoma of Head and Neck · China2UNKNOWNOct 31, 202394
NCT04811118Advanced Solid Tumors · China1UNKNOWNOct 31, 202227

How it is read

Names in the registry

  • “Docetaxel”, 93 entries
  • “docetaxel”, 37 entries
  • “Taxotere”, 9 entries
  • “HB1801”, 8 entries
  • “Docetaxel for injection (Albumin-bound)”, 4 entries

Codes read as this program: CKD810.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.